Witty: Industry must step up to help create new value system
This article was originally published in Scrip
The pharmaceutical industry must commit to "real innovation" and open mindedness if it is to become a thought leader in the debate about delivering and defining value for payers, said Andrew Witty, president of the European pharmaceutical industry federation, EFPIA, at its annual meeting this week.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.